A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
Not Applicable
Not yet recruiting
- Conditions
- ChlamydiaGonorrheaHivSyphilis
- Registration Number
- NCT06428643
- Lead Sponsor
- Tulane University
- Brief Summary
This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 2322
Inclusion Criteria
- Identifies as African American or Black
- 15-26 years of age
- Lives or spends most of their time in Orleans Parish
- Had vaginal sex at least once
Exclusion Criteria
- Unwilling or unable to provide informed consent
- Unable to speak or understand English
- Previously enrolled in the study
- Known to be pregnant
- Known HIV positive status
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Rate of chlamydia in women up to 60 months Primary outcome
- Secondary Outcome Measures
Name Time Method Rate of gonorrhea in women up to 60 months Secondary outcome
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive Chlamydia trachomatis resistance to standard antibiotic treatments in Black youth populations?
How does the Seek, Test, and Treat intervention compare to traditional STI screening protocols in reducing Chlamydia disparities among adolescents in the Deep South?
Which host biomarkers correlate with increased risk of Chlamydia, gonorrhea, or syphilis in Black youth, and can they predict response to expedited partner therapy?
What adverse events are associated with azithromycin and doxycycline treatment regimens for Chlamydia trachomatis in young, sexually active populations?
Are there novel combination therapies or prophylactic strategies targeting Chlamydia, gonorrhea, and HIV that could complement the NCT06428643 intervention model?